Lambda Therapeutic Research Ltd.
Quick facts
Phase 3 pipeline
- Denosumab-Ref · Oncology, Bone Metabolism
Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), preventing osteoclast formation and bone resorption.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: